Novo and Lilly battle over GLP-1 claims only a head-to-head trial can answernews2026-04-02T15:31:07+00:00April 2nd, 2026|Endpoints News|
Drug substance maker raises prices due to energy crisis; SpectronRX gets $85Mnews2026-04-02T14:43:53+00:00April 2nd, 2026|Endpoints News|
Lipocine’s postpartum depression drug fails; AstraZeneca claims liver cancer winnews2026-04-02T14:42:52+00:00April 2nd, 2026|Endpoints News|
Trump is preparing 100% tariffs on some drugmakers, documents shownews2026-04-02T14:04:53+00:00April 2nd, 2026|Endpoints News|
Claim of ChatGPT treating Rosie the dog’s cancer stirs AI biotech debatenews2026-04-02T13:15:17+00:00April 2nd, 2026|Endpoints News|
OpenEvidence moves into prior authorization with AI startup Tandemnews2026-04-02T13:12:11+00:00April 2nd, 2026|Endpoints News|
Alto Neuroscience shelves schizophrenia cognitive impairment program after Phase 2 missnews2026-04-02T11:02:01+00:00April 2nd, 2026|Endpoints News|
Eli Lilly’s chief technology officer retires after 35 years; Astellas strategy exec resignsnews2026-04-02T11:00:47+00:00April 2nd, 2026|Endpoints News|
Immunovant’s FcRn drug fails in a pair of Phase 3 trials in thyroid eye diseasenews2026-04-02T09:54:01+00:00April 2nd, 2026|Endpoints News|
